Takeda Pharmaceutical Company Share Price (NYSE: TAK)

$14.98

▲

0.01

(0.07%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Takeda Pharmaceutical Company Stock chart to analyse performance

Takeda Pharmaceutical Company stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$14.92
Today's High:$15.00
$14.98
0.4%
Downside
Day's Volatility :0.53%
Upside
0.13%
52 Weeks Low:$12.80
52 Weeks High:$15.56
$14.98
14.55%
Downside
52 Weeks Volatility :17.71%
Upside
3.7%

Takeda Pharmaceutical Company Stock Returns

Period	Takeda Pharmaceutical Company Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	0.13%	3.6%	0.0%
6 Months	1.08%	-7.7%	0.0%
1 Year	0.47%	-12.6%	0.0%
3 Years	12.12%	8.4%	-3.0%

Takeda Pharmaceutical Company Limited Key Stats

Check Takeda Pharmaceutical Company key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$14.97
Open	$14.92
Today's High	$15.0
Today's Low	$14.92
Market Capitalization	$47.6B
Today's Volume	$1.7M
52 Week High	$15.555
52 Week Low	$12.8
Revenue TTM	$4.5T
EBITDA	$1.2T
Earnings Per Share (EPS)	$0.29
PE Ratio	51.69
Dividend Yield	4.44%
Profit Margin	3.06%
Quarterly Earnings Growth YOY	0.31%
Return On Equity TTM	1.87%

Stock Returns calculator for Takeda Pharmaceutical Company Stock including INR - Dollar returns

The Takeda Pharmaceutical Company stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Takeda Pharmaceutical Company investment value today

Current value as on today

₹1,05,427

Returns

₹5,427

(+5.43%)

Returns from Takeda Pharmaceutical Company Stock

₹402 (+0.40%)

Dollar Returns*

₹5,025 (+5.03%)

Indian investors sentiment towards Takeda Pharmaceutical Company Stock

-18%

Period: Aug 2, 2025 to Sep 1, 2025. Change in 30 Days versus previous period

Search interest for Takeda Pharmaceutical Company Stock from India on INDmoney has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Takeda Pharmaceutical Company Limited

Name
Holdings %
Name
Holdings %
Capital Research Global Investors
0.42%
Morgan Stanley - Brokerage Accounts
0.18%
Goldman Sachs Group Inc
0.14%
FMR Inc
0.12%
Brandes Investment Partners & Co
0.12%
Adage Capital Partners Gp LLC
0.11%

Analyst Recommendation on Takeda Pharmaceutical Company Stock

Rating

Trend

Buy

52%Buy

47%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Takeda Pharmaceutical Company(by analysts ranked 0 to 5 stars)

Takeda Pharmaceutical Company Share Price Target

What analysts predicted

Upside of 13.64%

Target:

$17.02

Current:

$14.98

Takeda Pharmaceutical Company share price target is $17.02, a slight Upside of 13.64% compared to current price of $14.98 as per analysts' prediction.

Takeda Pharmaceutical Company Stock Insights

Price Movement
In the last 7 days, TAK stock has moved down by -0.5%
Increasing Revenue
Takeda Pharmaceutical Company Limited has shown positive revenue growth over the last two quarters. Revenue increased from $1,053.4 billion to $1,106.68 billion, reflecting an average growth of 4.8% per quarter.
Increasing Net Profit
Takeda Pharmaceutical Company Limited has shown positive profit trends over the last two quarters. Their net profit increased from -103.2 billion to 124.24 billion dollars, representing an average increase of 183.1% per quarter.
TAK vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 9.2%
TAK vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 32.2% return, outperforming this stock by 23.1%
Price to Sales
Takeda Pharmaceutical Company Limited has a Price-to-Sales Ratio where investors are willing to pay $0.00 for every $1 of sales. In comparison, Neurocrine Biosciences Inc. has a significantly higher Price-to-Sales Ratio of $5.60 for every $1 of sales. This indicates that investors currently see no value in Takeda's sales, whereas they are willing to pay a premium for Neurocrine's sales.

Takeda Pharmaceutical Company Limited Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$30.6B	↑ 56.93%
Net Income	$411.6M	↓ 59.46%
Net Profit Margin	1.34%	↓ 3.86%

	FY21	Y/Y Change
Revenue	$29.4B	↓ 2.84%
Net Income	$3.5B	↑ 749.9%
Net Profit Margin	11.76%	↑ 10.42%

	FY22	Y/Y Change
Revenue	$30.2B	↑ 11.61%
Net Income	$1.9B	↓ 38.81%
Net Profit Margin	6.45%	↓ 5.31%

	FY23	Y/Y Change
Revenue	$30.1B	↑ 12.85%
Net Income	$2.4B	↑ 37.8%
Net Profit Margin	7.87%	↑ 1.42%

	FY24	Y/Y Change
Revenue	$28.5B	↑ 5.87%
Net Income	$961.7M	↓ 54.56%
Net Profit Margin	3.38%	↓ 4.49%

	FY25	Y/Y Change
Revenue	$30.7B	↑ 7.45%
Net Income	$723.8M	↓ 25.08%
Net Profit Margin	2.36%	↓ 1.02%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$7.0B	↓ 5.43%
Net Income	$-20.1M	↓ 102.85%
Net Profit Margin	-0.29%	↓ 9.8%

	Q2 FY24	Q/Q Change
Revenue	$7.6B	↑ 14.95%
Net Income	$602.7M	↓ 3256.0%
Net Profit Margin	7.88%	↑ 8.17%

	Q3 FY24	Q/Q Change
Revenue	$8.2B	↓ 2.65%
Net Income	$642.9M	↓ 3.36%
Net Profit Margin	7.83%	↓ 0.05%

	Q4 FY24	Q/Q Change
Revenue	$7.4B	↓ 2.71%
Net Income	$154.4M	↓ 74.16%
Net Profit Margin	2.08%	↓ 5.75%

	Q1 FY25	Q/Q Change
Revenue	$7.1B	↓ 7.93%
Net Income	$-692.1M	↓ 533.81%
Net Profit Margin	-9.8%	↓ 11.88%

	Q2 FY25	Q/Q Change
Revenue	$1.1T	↑ 5.06%
Net Income	$124.2B	↓ 220.39%
Net Profit Margin	11.23%	↑ 21.03%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$20.5B	↑ 53.14%

	FY21	Y/Y Change
Profit	$20.3B	↑ 0.09%

	FY22	Y/Y Change
Profit	$20.8B	↑ 11.74%

	FY23	Y/Y Change
Profit	$20.8B	↑ 13.05%

	FY24	Y/Y Change
Profit	$18.9B	↑ 1.76%

	FY25	Y/Y Change
Profit	$20.1B	↑ 5.97%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$3.2B	↓ 34.18%

	Q2 FY24	Q/Q Change
Profit	$4.2B	↑ 36.66%

	Q3 FY24	Q/Q Change
Profit	$5.5B	↑ 18.77%

	Q4 FY24	Q/Q Change
Profit	$4.7B	↓ 6.97%

	Q1 FY25	Q/Q Change
Profit	$4.5B	↓ 7.69%

	Q2 FY25	Q/Q Change
Profit	$722.0B	↑ 7.55%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$6.2B	↑ 103.89%
Investing Cash Flow	$2.7B	↓ 110.3%
Financing Cash Flow	$-9.4B	↓ 134.12%

	FY21	Y/Y Change
Operating Cash Flow	$9.3B	↑ 50.94%
Investing Cash Flow	$3.6B	↑ 34.72%
Financing Cash Flow	$-10.0B	↑ 8.27%

	FY22	Y/Y Change
Operating Cash Flow	$9.5B	↑ 11.1%
Investing Cash Flow	$-1.7B	↓ 150.35%
Financing Cash Flow	$-9.0B	↓ 1.66%

	FY23	Y/Y Change
Operating Cash Flow	$7.3B	↓ 13.0%
Investing Cash Flow	$-4.5B	↑ 206.42%
Financing Cash Flow	$-5.3B	↓ 33.74%

	FY24	Y/Y Change
Operating Cash Flow	$4.8B	↓ 26.69%
Investing Cash Flow	$-3.1B	↓ 23.59%
Financing Cash Flow	$-2.4B	↓ 50.02%

	FY25	Y/Y Change
Operating Cash Flow	$7.1B	↑ 47.58%
Investing Cash Flow	$-2.5B	↓ 20.87%
Financing Cash Flow	$-5.0B	↑ 112.02%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.8B	↑ 86.05%
Investing Cash Flow	$-514.4M	↑ 2.38%
Financing Cash Flow	$-243.9M	↓ 62.63%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$1.0B	↓ 41.51%
Investing Cash Flow	$-1.0B	↑ 109.23%
Financing Cash Flow	$2.1B	↓ 1008.35%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$2.0B	↑ 76.29%
Investing Cash Flow	$-524.8M	↓ 53.4%
Financing Cash Flow	$-768.6M	↓ 133.16%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$2.5B	↑ 36.59%
Investing Cash Flow	$-749.9M	↑ 53.8%
Financing Cash Flow	$-4.3B	↑ 496.09%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.5B	↓ 42.11%
Investing Cash Flow	$-132.0M	↓ 82.97%
Financing Cash Flow	$-2.0B	↓ 53.99%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$215.4B	↓ 3.03%
Investing Cash Flow	$-33.2B	↑ 68.66%
Financing Cash Flow	$-214.9B	↓ 28.79%

Takeda Pharmaceutical Company Technicals Summary

Sell

Neutral

Buy

Takeda Pharmaceutical Company is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Takeda Pharmaceutical Company Limited Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Takeda Pharmaceutical Company Limited	5.12%	1.08%	0.47%	12.12%	-17.27%
Haleon Plc Spon Ads	3.05%	-8.15%	-3.54%	68.97%	32.25%
United Therapeutics Corporation	4.14%	-1.24%	-13.52%	37.06%	71.39%
Zoetis Inc.	3.02%	-7.95%	-14.8%	-0.28%	-1.51%
Neurocrine Biosciences Inc.	9.03%	23.42%	11.59%	35.51%	26.03%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Takeda Pharmaceutical Company Limited	51.69	51.69	0.43	0.0	0.02	0.02	0.04	4395.19
Haleon Plc Spon Ads	21.78	21.78	3.17	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.89	11.89	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Takeda Pharmaceutical Company Limited	Buy	$47.6B	-17.27%	51.69	3.06%
Haleon Plc Spon Ads	Buy	$43.9B	32.25%	21.78	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.39%	11.89	40.36%
Zoetis Inc.	Buy	$69.3B	-1.51%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	26.03%	41.3	13.88%

Takeda Pharmaceutical Company Dividend announcements

Takeda Pharmaceutical Company Dividends March, 2022
In the quarter ending March,2022. Takeda Pharmaceutical Company has declared dividend of $0.33

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Organization	Takeda Pharmaceutical Company
Employees	47455
CEO	Mr. Christophe Weber
Industry	Health Technology

Key Management of Takeda Pharmaceutical Company Limited

Name	Title
Mr. Christophe Weber	President, CEO & Representative Director
Mr. Milano Furuta	CFO & Director
Dr. Andrew S. Plump M.D., Ph.D.	President of Research & Development and Representative Director
Dr. Seigo Izumo	Chair of Management Board
Mr. Haruhiko Hirate	Member of Management Board
Mr. Salvatore Alesci M.D., Ph.D.	Member of Management Board and Head of R&D Global Science & Biomedical Policy
Norimasa Takeda	Chief Accounting Officer & Corporate Controller
Mr. Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department
Mr. Gabriele Ricci	Chief Data & Technology Officer
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Finance

Important FAQs about investing in TAK Stock from India :

What is Takeda Pharmaceutical Company share price today?

Takeda Pharmaceutical Company share price today is $14.98 as on August 30, 2025 at 1:29 am IST at the close of the market. Takeda Pharmaceutical Company share today touched a day high of $15.00 and a low of $14.92.

What is the 52 week high and 52 week low for Takeda Pharmaceutical Company share?

Takeda Pharmaceutical Company share touched a 52 week high of $15.56 and a 52 week low of $12.80. Takeda Pharmaceutical Company stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $14.98, lower by 3.7% versus the 52 week high.

How to invest in Takeda Pharmaceutical Company Stock (TAK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Takeda Pharmaceutical Company on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Takeda Pharmaceutical Company Shares that will get you 0.1001 shares as per Takeda Pharmaceutical Company share price of $14.98 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Takeda Pharmaceutical Company Stock (TAK) from India?

Indian investors can start investing in Takeda Pharmaceutical Company (TAK) shares with as little as ₹88.1475 or $1 (as of September 02, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.47 in Takeda Pharmaceutical Company stock (as per the Rupee-Dollar exchange rate as on September 02, 2025). Based on Takeda Pharmaceutical Company share’s latest price of $14.98 as on August 30, 2025 at 1:29 am IST, you will get 0.6676 shares of Takeda Pharmaceutical Company. Learn more about fractional shares .

What are the returns that Takeda Pharmaceutical Company has given to Indian investors in the last 5 years?

Takeda Pharmaceutical Company stock has given -17.27% share price returns and 20.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?